Core Insights - The APOLLO study demonstrates promising efficacy and safety for MT-601 in patients with relapsed lymphoma, with 78% of patients achieving objective response rates and 44.4% showing complete response [1][4][10] Safety - MT-601 infusion was well tolerated among all participants, with no cases of immune-effector cell associated neurotoxicity syndrome (ICANS) reported and only one instance of Grade 1 cytokine release syndrome (CRS) [3][11] - No dose limiting toxicities (DLTs) have been reported to date [3] Efficacy - In the first dose cohort, 7 out of 9 patients achieved objective responses (78%) at the first response assessment, with 4 patients demonstrating complete response (CR; 44.4%) [4][7] - Immunomonitoring data indicated that lymphodepletion enhanced the expansion and persistence of MAR-T cell clones in vivo [2] Follow-Up - Long-term follow-up data is available for three patients, with ongoing visits to assess the durability of responses [5][8] - The longest follow-up period recorded is 12 months for one patient, with two patients showing complete response (CR) and partial response (PR) at 6 months [8] Company Overview - Marker Therapeutics, Inc. is focused on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors, with MT-601 being a multi-antigen recognizing (MAR) T cell product targeting six tumor antigens [13][16] - The APOLLO trial is a Phase 1, multicenter, open-label study evaluating the safety and efficacy of MT-601 in patients with relapsed or refractory lymphoma who have failed or are ineligible for anti-CD19 CAR-T cell therapy [14]
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma